Education
About Us
Working with TipRanks
Follow Us
Orexo AB (ORXOF)
OTHER OTC:ORXOF
ORXOF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.08 - $2.39
Previous CloseN/A
Volume3.00K
Average Volume (3M)0.00
Market Cap
$73.34M
Enterprise Value$1.10B
Total Cash (Recent Filing)$121.30M
Total Debt (Recent Filing)$495.60M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Oct 23, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding34,710,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-4.78
Price to Sales (P/S)1.02
P/FCF Ratio-16.21
Enterprise Value/Market Cap15.04
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit2.25
Enterprise Value/Ebitda39.40
Forecast
1Y Price Target
$2.19Price Target Upside1.86% Upside
Rating ConsensusHold
Number of Analyst Covering0
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.08 and its highest was $2.39 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $73.34M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 23, 2025 which is in 56 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2025. The company reported -$0.125 earnings per share for the quarter, missing the consensus estimate of -$0.039 by -$0.087.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Undervalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.05.
How many shares outstanding does Orexo AB have?
Orexo AB has 34,710,640 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.125 in its last earnings report, missing expectations of -$0.039. Following the earnings report the stock price went down -6.731%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with notable achievements in ZUBSOLV demand stabilization in the Commercial segment and promising developments in the AmorphOX platform. However, these were offset by challenges such as the decline in ZUBSOLV revenues, delays in OX124 approval, and increased legal costs, which impacted financial performance and raised liquidity concerns.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―